Covering these 6 diseases and 1 expert consensus, the "Guidelines for the Management of Chronic Insomnia and Chronic Diseases in the Elderly Series" has been released in Shanghai. The Guidelines for the Management of Chronic Insomnia and Chronic Diseases in the Elderly | Lipids | Diseases
There are more than 290 million people with cardiovascular diseases, 266 million people with hypertension, 290 million people with obesity, 114 million people with diabetes, 280 million people with dyslipidemia, 340 million people with smoking, and 890 million people with second-hand smoke
On the 1st, Chen Kaixian, an academician of the CAS Member and a researcher of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, cited a series of domestic data to alert Chinese people to the soaring incidence rate of chronic diseases, which poses a serious challenge. He also quoted Academician Chen Zhu, President of the Red Cross Society of China, as saying, "Without effective control, China will experience a severe situation of chronic disease 'blowout' in the next 30 years."
At the 2023 China Elderly Chronic Disease Conference, which opened in Shanghai on the same day, the "Scientific Prevention and Treatment of Chronic Diseases, Helping Elderly Health" series of guidelines for the management of chronic diseases in the elderly were released, covering six diseases and one expert consensus.
In promoting the prevention and treatment of chronic diseases in the elderly, standards should be prioritized. The Jiefang Daily Shangguan News reporter learned that the Chinese Gerontology and Geriatrics Society has established an expert committee and organized nationally renowned experts and scholars in traditional Chinese and Western medicine to develop a series of guidelines for the management of chronic diseases in the elderly population to standardize their behavior. The expert team for the compilation of the entire guide strictly follows the requirements of the society's group standards, conducts standard drafting work in groups, and recently completed the compilation of the guide, which has been reviewed and published by the society.
Professor Gao He, Vice President of the Chinese Gerontology and Geriatrics Society, announced that the seven guidelines/consensus include: Guidelines for the Management of Chronic Obstructive Pulmonary Disease in the Elderly, Guidelines for the Management of Chronic Diseases of Type 2 diabetes in the Elderly, Guidelines for the Management of Chronic Insomnia in the Elderly, Guidelines for the Management of Chronic Diseases of Osteoarthritis in the Elderly, Guidelines for the Management of Chronic Diseases of Osteoporosis in the Elderly, Guidelines for the Management of Chronic Diseases of Prostatic Hyperplasia in the Elderly, and Expert Consensus on Clinical Application of Linggui Zhugan Granules.
It is worth noting that regarding the clinical application of Linggui Zhugan Granules, the first classic Chinese medicine compound developed in cooperation with Shanghai and Jiangsu universities and enterprises - Linggui Zhugan Granules has been approved for marketing. It is reported that this is the first traditional Chinese medicine compound formulation managed according to the ancient classic prescription catalog in China, exploring a new path for the registration of classic famous prescriptions and new drugs.
The picture shows the opening of the exhibition of modern Chinese medicine books and periodicals in the collection of Shanghai Museum of Traditional Chinese Medicine. The collection of books by the renowned Chinese medicine expert Yan Erling was donated to the museum
Ling Gui Zhu Gan Tang is derived from Zhang Zhongjing's "Jin Kui Yao Lue" during the Eastern Han Dynasty. It is a representative formula for the treatment of "phlegm and Yin disease" using the Wen Yang Hua Yin method. It consists of four herbs: Poria cocos, Gui Zhi, Bai Zhu, and Gan Cao. It is the 19th prescription in the "Catalogue of Ancient Classic Prescriptions" published by the State Administration of Traditional Chinese Medicine, and the first prescription in the "Key Information Table of Ancient Classic Prescriptions".
Shanghai University of Traditional Chinese Medicine and Jiangsu Kangyuan Pharmaceutical Co., Ltd. jointly undertook the research task of the national "13th Five Year Plan" "major new drug innovation" science and technology major project - "research and development of classic famous prescriptions based on Chinese medicine classics", with Xiao Wei, academician of the CAE Member as the project leader.
Last year, Professor Ji Guang's research team at the Spleen and Stomach Disease Research Institute of Longhua Hospital Affiliated to Traditional Chinese Medicine made significant progress in the prevention and treatment of non-alcoholic fatty liver disease with traditional Chinese medicine, providing high-level evidence-based evidence for the effectiveness and safety of Linggui Zhugan Tang in treating NAFLD with spleen yang deficiency syndrome.
In addition to chronic obstructive pulmonary disease, diabetes, insomnia, arthritis, osteoporosis, benign prostatic hyperplasia and other diseases involved in the Chronic Disease Management Guide, non-alcoholic fatty liver disease is the most common chronic liver disease in clinical practice, and the prevalence of NAFLD in China has reached 29.88%. NAFLD is also one of the advantageous diseases in traditional Chinese medicine intervention, belonging to the categories of "liver fetish" and "phlegm and yin" in traditional Chinese medicine.
Therefore, based on previous clinical cohort studies, the research team proposed the core syndrome pathogenesis of "Spleen Yang Deficiency" in NAFLD. On the basis of establishing a disease syndrome combined with metabolic risk prediction model, and under the guidance of the traditional theory in "Jin Kui Yao Lue" that "for patients with phlegm syndrome, warm medicine should be used to harmonize, and Ling Gui Zhu Gan Tang should be the main treatment", the team pioneered the use of Ling Gui Zhu Gan Tang for the treatment of NAFLD, forming a clinical feature of treating fatty liver from the perspective of "phlegm syndrome".
Chen Qun, Vice Chairman of the Shanghai Municipal Committee of the Chinese People's Political Consultative Conference, and others attended the conference.